Strategic Partnerships Leverage recent distribution partnerships with AvMEDICAL to expand CyPath Lung reach, targeting federal customers such as the VA and other government-sponsored healthcare programs for noninvasive lung cancer diagnostics.

Clinical Adoption Highlight CyPath Lung as a noninvasive, high-sensitivity test that can increase diagnostic accuracy for patients with pulmonary nodules, positioning it as a primary adjunct to imaging workflows in early lung cancer detection.

Commercial Momentum Capitalize on conference activity and poster presentations at NAVREF to generate leads among nontraditional healthcare networks, patient advocacy groups, and clinical researchers interested in noninvasive diagnostic tools.

Market Expansion Promote CyPath Lung's Laboratory Developed Test licensing path to expand adoption across pathology laboratories and regional centers, emphasizing reduced unnecessary invasive procedures and potential cost savings.

Portfolio Synergy Explore growth by aligning with the extracorporeal immunoadsorption platform initiative for inflammatory conditions as a cross-sell opportunity to research centers pursuing multi-therapy approaches and integrated diagnostics.